Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study
03:02pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study
12:03pm, Thursday, 18'th Aug 2022
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
08:59am, Thursday, 18'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced it plans to explore the potential development of a novel monkeypox vac
Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data
06:56pm, Wednesday, 17'th Aug 2022 Benzinga
Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM).
The topline data indicates that the tria
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
05:04pm, Wednesday, 17'th Aug 2022 Benzinga
Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.
Blueprint Medicines Corporation (NASDAQ: BPMC) fell 22.5% to $53.11 af
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
04:03pm, Wednesday, 17'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus
U.S. Stocks Open Lower; Nasdaq Down 150 Points
02:36pm, Wednesday, 17'th Aug 2022 Benzinga
U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday.
The Dow traded down 0.52% to 33,973.33 while the NASDAQ fell 1.18% to 12,947.89. The S&P al
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
09:42am, Wednesday, 17'th Aug 2022
Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As 'Long-Awaited'
Blueprint's stock falls 11% after sharing new Phase 2 data for its rare-disease therapy
08:10am, Wednesday, 17'th Aug 2022
Shares of Blueprint Medicines Corp. BPMC, -2.00% tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic
Where Blueprint Medicines Stands With Analysts
07:57pm, Wednesday, 03'rd Aug 2022 Benzinga
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
5
1
1
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark
02:45pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark
12:02pm, Wednesday, 03'rd Aug 2022
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
12:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines Corporation's (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call Transcript
11:31am, Tuesday, 02'nd Aug 2022
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Havilan
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
09:50am, Tuesday, 02'nd Aug 2022
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
